Trials / Completed
CompletedNCT02642432
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 146 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of ABT-493/ABT-530 following 12 weeks of treatment in adults with chronic Hepatitis C Virus Infection genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-493/ABT-530 | Tablet; ABT-493 coformulated with ABT-530 |
Timeline
- Start date
- 2015-12-07
- Primary completion
- 2016-10-27
- Completion
- 2017-02-10
- First posted
- 2015-12-30
- Last updated
- 2021-07-13
- Results posted
- 2017-09-26
Source: ClinicalTrials.gov record NCT02642432. Inclusion in this directory is not an endorsement.